Showing results (1-10 of 86) with videos related to
Sort By:
Pageof 9
Expert Opinion on Biological Therapy|March 30, 2024
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategiesMatteo Molica, Marco RossiExpert Review of Hematology|October 22, 2022
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid TumoursMatteo Molica, Salvatore PerroneLeukemia Research|December 3, 2014
How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated reviewMassimo Breccia, Matteo Molica, Giuliana AlimenaMediterranean Journal of Hematology and Infectious Diseases|September 21, 2020
Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid LeukemiaMatteo Molica, Elisabetta Abruzzese, Massimo BrecciaCurrent Cancer Drug Targets|October 4, 2017
Ponatinib: A Review of Efficacy and SafetyFulvio Massaro, Matteo Molica, Massimo BrecciaJournal of Clinical Medicine|June 10, 2023
Gilteritinib: The Story of a Proceeding Success into Hard-to-TreatMatteo Molica, Salvatore Perrone, Marco RossiExpert Opinion on Pharmacotherapy|December 1, 2016
Second line small molecule therapy options for treating chronic myeloid leukemiaMatteo Molica, Fulvio Massaro, Massimo BrecciaInternational Journal of Hematologic Oncology|October 11, 2018
Current first- and second-line treatment options in acute promyelocytic leukemiaFulvio Massaro, Matteo Molica, Massimo BrecciaExpert Opinion on Pharmacotherapy|August 5, 2021
Drug treatment options for acute promyelocytic leukemiaFelicetto Ferrara, Matteo Molica, Massimo BernardiExpert Review of Hematology|December 17, 2016
How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changesFulvio Massaro, Matteo Molica, Massimo BrecciaPageof 9